GLENMARK PHARMACEUTICALS LTD. - 532296 - Glenmark Pharmaceuticals Ltd. To Divest Select Brands And Sub-Brands ('Tail Brands') From Its Dermatology Segment, For India And Nepal Territories, To Eris Oaknet Healthcare Private Limited.
Glenmark Pharmaceuticals Ltd. to divest select brands and sub-brands ('Tail Brands') from its dermatology segment, for India and Nepal territories, to Eris Oaknet Healthcare Private Limited.
Glenmark pharma launches generic version of Novartis' heart failure drug
Opens floodgates for more generic launches; 40 new brands expected GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Enclosed please find herewith the details of Earnings Call slated for Monday, February 13, 2023 at 9:30 a.m. - 10:30 a.m. (IST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call. GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Heart failure treatment becomes more affordable with Glenmark launching the Sacubitril + Valsartan tablets in India GLENMARK PHARMACEUTICALS LTD. - 532296 - Closure of Trading Window
We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, February 10, 2023, inter alia, to consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2022. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from December 31, 2022 to February 12, 2023 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2022. GLENMARK PHARMACEUTICALS LTD. - 532296 - Board Meeting Intimation for Unaudited Financial Results Of The Company For The Third Quarter And Nine Months Ended December 31, 2022
GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2023 ,inter alia, to consider and approve We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, February 10, 2023, inter alia, to consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2022. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from December 31, 2022 to February 12, 2023 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2022.
Glenmark launches generic version of diuretic with $16.5-million market
Glenmark Pharmaceuticals will launch single-dose and multi-dose vials of Bumetanide injection USP, the company has said GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals launches Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials
F&O Call: Nandish Shah recommends to long Glenmark Pharma futures
The derivative analyst from HDFC Securities expects Glenmark Pharma January futues to test Rs 450 on the upside.
Glenmark Pharma launches combination drug for Type 2 diabetic patients
Glenmark Pharmaceuticals Ltd on Wednesday said it has launched triple fixed-dose combination Teneligliptin with Pioglitazone and Metformin in India for diabetic patients. This fixed-dose combination offers patients with Type 2 diabetes the convenience of once daily dosing to improve their glycemic control. It is priced at Rs 14.90 per day, thereby reducing the daily cost of therapy by 40 per cent, making it more affordable to the masses, the company said in a statement. It has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg), Pioglitazone (15 mg) and Metformin (500mg/1000mg) in a sustained release (SR) formulation, it added. "Type 2 diabetes patients in India often face issues of beta cell dysfunction along with insulin resistance. In fact, the prevalence of high insulin resistance in India is 38 per cent compared to the global incidence of 15 per cent," Glenmark Pharmaceuticals EVP & Business Head - India Formulations Alok Malik said. The market .